Axon Enterprise vs. DocuSign: Which Industrials Stock Is a Better Buy in 2026?

Source The Motley Fool

Key Points

  • Axon Enterprise maintains a powerful ecosystem by integrating public safety hardware with cloud-based software services.

  • DocuSign is leveraging its massive user base to expand from e-signatures into comprehensive intelligent agreement management.

  • Which of these high-growth companies is the better fit for your portfolio in 2026?

  • These 10 stocks could mint the next wave of millionaires ›

Should I prioritize high-growth public safety tech or a cash-generating software leader? Deciding between Axon Enterprise (NASDAQ:AXON) and Docusign Inc. (NASDAQ:DOCU) requires looking closely at their unique market positions today.

Axon provides essential hardware and cloud services to law enforcement, while Docusign dominates the digital agreement space. Although they serve different industries, both firms rely on subscription-based software models to drive recurring revenue and long-term stability. This comparison explores which business offers a more compelling balance of growth and valuation for long-term investors.

The case for Axon Enterprise

Axon Enterprise builds integrated hardware and cloud software for public safety. Its product suite includes Taser devices, body cameras, and digital evidence management. Its primary customers are U.S. federal, state, and local law enforcement agencies. By connecting physical devices to a cloud-based ecosystem, the company creates high switching costs for its users. No customer represented more than 10% of sales in its latest annual report.

In the fiscal year ended Dec. 31, 2025, revenue reached around $2.8 billion, representing growth of approximately 33.5% year over year. The company reported net income of roughly $124.9 million. This resulted in a net margin of close to 4.5%, a figure that describes what percentage of revenue remains as profit after all expenses. While top-line growth remains robust, net income levels can fluctuate based on investment in new product lines.

As of its December 2025 balance sheet, the current ratio is approximately 2.5x. This metric measures a company's ability to cover short-term obligations with assets that can be converted to cash within a year. The debt-to-equity ratio is roughly 0.6x, indicating that total debt is about 60% of shareholder equity. Free cash flow, which is cash from operations minus capital expenditures, was about $75.1 million. Note that stock-based compensation represented roughly 300% of operating cash flow, meaning reported cash generation is heavily inflated by this non-cash add-back.

The case for Docusign

Docusign is a leader among tech stocks, providing software for intelligent agreement management. The company helps organizations create, sign, and manage contracts through its eSignature platform. It serves over 1.8 million paying customers, including large enterprises and small businesses. No single customer accounted for more than 10% of revenue in its most recent fiscal year. It grows through a partner ecosystem that includes integrations with platforms like Microsoft Corp. (NASDAQ:MSFT) and Salesforce.com Inc. (NYSE:CRM).

In the fiscal year ended Jan. 31, 2026, revenue reached about $3.2 billion. This was an increase of approximately 8.2% compared with the prior fiscal year. Net income for the period was roughly $309 million, leading to a net margin of around 9.6%. The company is focused on expanding its reach beyond simple signatures into broader contract lifecycle management to sustain growth.

As of its January 2026 balance sheet, the debt-to-equity ratio is roughly 0.1x. This low figure suggests the company uses very little debt relative to its equity. The current ratio is approximately 0.7x, suggesting its short-term assets are less than its short-term liabilities. Free cash flow reached about $1.1 billion. Note that stock-based compensation (SBC) represented roughly 53.4% of operating cash flow, which inflates reported cash generation since SBC is a non-cash expense added back in the cash flow statement.

Risk profile comparison

Axon Enterprise faces risks related to its heavy reliance on the law enforcement vertical. Budgetary constraints or negative publicity surrounding policing can reduce demand for its core products. The company also deals with supply chain risks for components used in Taser devices. Rapid technological shifts in artificial intelligence could threaten its software market share. Additionally, the business carries risks of product liability claims stemming from the use of its public safety equipment.

Docusign must navigate intense competition from large rivals like Adobe Inc. (NASDAQ:ADBE) and Microsoft. Most of its revenue currently comes from eSignature products, making it dependent on the successful rollout of its new agreement management platform. The company is a target for cyberattacks because it handles sensitive data, which creates significant privacy risks. It also relies on third-party infrastructure for its services. Scaling international operations remains a challenge due to varying global regulations.

Valuation comparison

Axon Enterprise carries a significantly higher valuation than Docusign, reflecting its faster revenue growth and its dominant position in a specialized niche of the public safety market.

MetricAxon EnterpriseDocuSign
Forward P/E49.8x16.6x
P/S ratio9.7x4.3x

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

Which stock would I buy in 2026?

The launch and expansion of Docusign's IAM platform, along with the introduction of AI-powered tools, position the company well for future growth. Still, the leveling off in its projected revenue growth rate implies that Docusign may be entering a phase of more mature, less dramatic expansion as it navigates the competitive landscape in the digital agreement and contract management space.

That moderation is seen in the revenue growth of about 9.4% for fiscal year 2027 to $3.5 billion. Net income growth should be a little better, at 12%, to nearly $350 million.

Axon Enterprise has a fine outlook for growth as law enforcement is increasingly equipped with Tasers and the public is becoming increasingly demanding that agents wear body cameras. Its cloud-based evidence control system is also an increasingly desired service for law enforcement organizations, too.

Expansion into Europe and Canada should also help, as should a focus on producing personal consumer-protection devices. In particular, all the data and video created by Axon customers have to be managed, and the company is seeing strong demand for its AI-based management systems from customers who find many of the services create efficiencies within their operations.

In its fiscal 2026, sales are seen growing well, up about a third to $3.7 billion, with net income of around $290 million and free cash flow of $425 million, well over 2025's levels.

While Axon's growth rates are more impressive than Docusign's, the stock commands quite the premium in the market. That gives Docusign the nod given its reasonable forward P/E and P/S ratios.

Missed AI’s "Act 1"? Act 2 Could Be 14x Bigger

Most investors think they missed the AI boat because they didn't buy Nvidia in 2005.

But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout, a massive technology build-out that Google’s CEO says could be more profound than fire or electricity.

While everyone watches the chip designers, one "backbone" company provides the critical technology that Nvidia and AMD literally cannot function without. We’ve detailed this under-the-radar player in our new AI Playbook.

Continue »

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Adobe, Axon Enterprise, Docusign, Microsoft, and Salesforce. The Motley Fool recommends the following options: long January 2028 $330 calls on Adobe and short January 2028 $340 calls on Adobe. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Anthropic files for a $2 trillion IPO — the $80.7 billion loss is the decoy, the $450 billion compute bill is the riskAnthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
Author  Irene Q.
Oct 27, Tue
Anthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
placeholder
Brent's $115 front month sits $4.6 above January — the $14 spread to WTI is the supply-risk premiumDecember Brent trades at $115.29 while January is $110.71, a $4.58 backwardation. The December Brent-WTI spread is $14.2, versus a $3-5 normal. That gap, not the headline, is where the Middle East supply risk is priced. Here is what the curve says, why the December contract's expiry on October 30 will mechanically cut the headline by $4.6, and the 108.81 neckline that decides the next move.
Author  Irene Q.
Oct 28, Wed
December Brent trades at $115.29 while January is $110.71, a $4.58 backwardation. The December Brent-WTI spread is $14.2, versus a $3-5 normal. That gap, not the headline, is where the Middle East supply risk is priced. Here is what the curve says, why the December contract's expiry on October 30 will mechanically cut the headline by $4.6, and the 108.81 neckline that decides the next move.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 29, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 29, 2026. Read on for the details.
Author  Mitrade
Oct 29, Thu
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 29, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 30, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 30, 2026. Read on for the details.
Author  Mitrade
Yesterday 02: 21
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 30, 2026. Read on for the details.
placeholder
US GDP grew 3.4% and core PCE held at 3.1% — December is now a hike trade, not a cut tradeUS Q3 GDP rose 3.4%, above the 3.1% estimate, while September headline PCE hit 3.6% and core held at 3.1%. December hike odds are near 90%; inventories, AI capex and energy explain why.
Author  Irene Q.
23 hours ago
US Q3 GDP rose 3.4%, above the 3.1% estimate, while September headline PCE hit 3.6% and core held at 3.1%. December hike odds are near 90%; inventories, AI capex and energy explain why.
goTop
quote